Biocon Q4 Results: Profit Falls 56.8% to ₹198.6 Crore; Revenue Rises to ₹4,516.6 Crore

Biocon Q4 Results: 56.8% fall in Q4 net profit to ₹198.6 crore, while revenue rose to ₹4,516.6 crore. The company also announced a 50 paise dividend for FY26

By Srajan Agarwal | 2026-05-08T10:56:21.743348+05:30

Modern multi-story medical facility with contemporary architecture featuring a combination of light-colored stone or concrete exterior walls and extensive glass curtain wall sections.

Biocon Ltd reported a sharp fall in its consolidated net profit for the fourth quarter ended March 31, 2026. The company’s profit dropped 56.8% year-on-year to ₹198.6 crore, mainly due to a one-time exceptional expense of ₹80.4 crore.

In the same quarter last year, Biocon had posted a consolidated net profit of ₹459.4 crore.

Key Highlights of Biocon Q4 Results

Net profit: ₹198.6 crore, down 56.8% from ₹459.4 crore in the year-ago quarter.
Revenue from operations: ₹4,516.6 crore, slightly higher than ₹4,417 crore reported in the same quarter last year.
Total expenses: Rose to ₹4,241.2 crore compared to ₹3,987.5 crore a year earlier.
Exceptional expense: The company recorded an outgo of ₹80.4 crore under various heads, including the impact of the new labour code.
Dividend: Biocon’s board has recommended a final dividend of 50 paise per equity share of face value ₹5 for FY26, subject to shareholder approval.

Also Read: Paytm Q4 Results: One97 Communications Posts ₹183 Crore Profit, Shares Rise Over 6%

Full-Year FY26 Performance

For the full financial year 2025-26, Biocon’s consolidated net profit stood at ₹368.8 crore, significantly lower than ₹1,429.4 crore reported in FY25.

However, the company’s revenue from operations increased to ₹16,927 crore in FY26, compared to ₹15,261.7 crore in the previous financial year.

Biocon Executive Chairperson Kiran Mazumdar-Shaw said the company ended FY26 on a strong note despite a challenging global environment.

She said Biocon delivered margin expansion and 13% year-on-year growth in operating revenue, excluding the one-time impact of generic lenalidomide sales in the previous year.

According to her, the performance reflects the company’s business resilience and disciplined execution during an important year of integration.

Also Read: M&M Q4 Results: Mahindra PAT Jumps 42% to Rs 4,668 Cr, Revenue Rises 29%

Business Restructuring and Leadership Changes

Biocon has created a unified biopharma entity by integrating its biosimilars business with its generics formulations and APIs business.

The company said this combined structure is expected to strengthen its balance sheet, improve leverage metrics and expand its global commercial presence.

Biocon also announced key leadership changes. Shreehas Tambe took charge as CEO and Managing Director of Biocon Ltd from April 1, 2026, while Kedar Upadhye has been appointed as Chief Financial Officer.

You May Also Like -

PNB Q4 Results: Net Profit Rises to ₹5,225 Cr; ₹3 Dividend Declared

Aditya Birla Capital’s Q4 Profit Crosses ₹1,100 Crore, Lending Book Tops ₹2 Lakh Crore

Source URL: https://news4bharat.com/q4-results/biocon-q4-results-profit-falls-revenue-rises-dividend-fy26/